ResMed Inc.
ResMed Inc. is classed by the SEC under Surgical & Medical Instruments & Apparatus (industry code 3841), based in San Diego, CA. In its latest annual figures on file, for the fiscal year ended 2025-06-30, it reported revenue of $5.1 billion and a profit of $1.4 billion (its filed statements).
vs its business-model standard
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 3841, Surgical & Medical Instruments & Apparatus); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 6.8 out of ten, 9 of 9 metrics filed: past 6.8 out of ten, present 7.8 out of ten, future 5.4 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
- Surviving crises (past): 5.5 out of ten. 1 warning event since 2017; the latest 2026-08-17. 55th percentile among 121 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Track record (past): 7.6 out of ten. +11.8% a year over 10 filed years; profitable in 10 of 10. 76th percentile among 105 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Shareholder treatment (past): 7.0 out of ten. Share count shrank 0.3% a year. 42% of cash flow returned. Insiders: 31 sales, 0 purchases. 70th percentile among 40 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Financial health (present): 7.8 out of ten. ROE 23%: 23¢ of profit per shareholder dollar. Leverage 27%: owes 27¢ per asset dollar. 78th percentile among 120 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Industry position (present): 7.8 out of ten. top 22% of 109 in its family; net margin 26.9%. 78th percentile among 109 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Leadership (present): 7.8 out of ten. top 22% of 90 in its family for leadership; chief executive since 2013. 78th percentile among 90 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
- Room to expand (future): 5.8 out of ten. top 42% of 104 in its family for room to expand. 58th percentile among 104 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Growth drivers (future): 5.2 out of ten. top 48% of 105 in its family for growth drivers. 52nd percentile among 105 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Expectations vs reality (future): 5.1 out of ten. top 49% of 88 in its family for expectations against reality. 51st percentile among 88 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-08-13 for the period ended 2026-06-30 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-05-01 for the period ended 2026-03-31 (on EDGAR). Newest results release: Form 8-K filed 2026-08-06 (on EDGAR). Newest filing: Form 4, 2026-10-08. Filings on record since 1996. Read from EDGAR 2026-10-12.
Where the revenue comes from
Lines of business in fiscal 2026: Sleep and Breathing Health 88%, Residential Care Software 12%. By geography: United States 63%, Rest of the World 37%. As tagged in its annual report (Form 10-K, filed 2026-08-13).
Who runs it
Farrell, Michael J. (Chairman and CEO); Farrell, Peter C (Chairman of the Board); Bloomer, Aaron (Chief Financial Officer); Sandercock, Brett (Chief Financial Officer); Leong, Justin (Chief Product Officer); Ghoshal, Kaushik (Chief Commercial Officer, SaaS); Rider, Michael J (Global General Counsel); De, Witte Jan (director); Mowad-Nassar, Nicole (director); Burt, Carol (director); and 7 more. 17 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-10-08.
This file: Overview · Past · Present · Future · Filings · every company on file
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.